Brookline Capital Downgrades Annovis Bio to Hold, Announces $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Brookline Capital analyst Tyler Bussian downgraded Annovis Bio (ANVS) from Buy to Hold and set a $9 price target.

February 28, 2024 | 11:51 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Annovis Bio was downgraded from Buy to Hold by Brookline Capital, with a new price target of $9.
The downgrade from Buy to Hold suggests a neutral to negative outlook on the stock's short-term performance. The new price target of $9, depending on the current stock price, could imply a downward adjustment in the stock's valuation expectations. This could lead to a decrease in investor confidence and potentially lower stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100